Choline alfoscerate

Drug Profile

Choline alfoscerate

Alternative Names: Brezal; Choline alphoscerate; Choline glycerophosphate; Delecit; Gliatilin

Latest Information Update: 05 Nov 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Italfarmaco
  • Developer Dong Wha Pharmaceutical; Italfarmaco
  • Class Antibacterials; Antidementias; Glycerophosphates; Glycerophospholipids; Neuroprotectants; Nootropics
  • Mechanism of Action Cell membrane permeability enhancers; Cholinergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cognition disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Mar 2003 A study has been added to the adverse events and therapeutic trials sections
  • 22 May 1998 Launched for Cognition disorders in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top